» Articles » PMID: 35892836

Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 27
PMID 35892836
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: MDSCs play an active role in the immune surveillance escape of cancer cells. Because MDSCs in mice are CD11bGr1, near-infrared photoimmunotherapy (NIR-PIT) using the NIR dye IR700 conjugated to an MDSC-binding antibody provides an opportunity for targeted elimination of MDSCs. (2) Methods: The efficacy of Gr1-IR700-mediated NIR-PIT was evaluated in vitro using magnetically separated CD11bGr1 MDSCs from spleens of 4T1-luc tumor-bearing (TB) mice. For in vivo evaluation, spleens of Gr1-IR700-injected 4T1-luc TB mice were irradiated with NIR light, and splenocyte viability was determined using CCK-8 assays. Metabolic profiling of NIR-PIT-irradiated spleens was performed using H MRS. (3) Results: Flow cytometric analysis confirmed a ten-fold increase in splenic MDSCs in 4T1-luc TB mice. Gr1-IR700-mediated NIR-PIT eliminated tumor-induced splenic MDSCs in culture. Ex vivo fluorescence imaging revealed an 8- and 9-fold increase in mean fluorescence intensity (MFI) in the spleen and lungs of Gr1-IR700-injected compared to IgG-IR700-injected TB mice. Splenocytes from Gr1-IR700-injected TB mice exposed in vivo to NIR-PIT demonstrated significantly lower viability compared to no light exposure or untreated control groups. Significant metabolic changes were observed in spleens following NIR-PIT. (4) Conclusions: Our data confirm the ability of NIR-PIT to eliminate splenic MDSCs, identifying its potential to eliminate MDSCs in tumors to reduce immune suppression. The metabolic changes observed may identify potential biomarkers of splenic MDSC depletion as well as potential metabolic targets of MDSCs.

Citing Articles

Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.

Nie S, Jing Y, Lu L, Ren S, Ji G, Xu H World J Gastrointest Oncol. 2024; 16(5):1690-1704.

PMID: 38764816 PMC: 11099432. DOI: 10.4251/wjgo.v16.i5.1690.


Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.

Mehdizadeh R, Shariatpanahi S, Goliaei B, Ruegg C Sci Rep. 2023; 13(1):5875.

PMID: 37041172 PMC: 10090155. DOI: 10.1038/s41598-023-32554-z.


Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.

Yamada M, Matsuoka K, Sato M, Sato K Pharmaceutics. 2023; 15(2).

PMID: 36839882 PMC: 9967863. DOI: 10.3390/pharmaceutics15020561.


Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.

Mohiuddin T, Zhang C, Sheng W, Al-Rawe M, Zeppernick F, Meinhold-Heerlein I Int J Mol Sci. 2023; 24(3).

PMID: 36768976 PMC: 9916513. DOI: 10.3390/ijms24032655.


Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer.

Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Hanai N Cancers (Basel). 2022; 14(22).

PMID: 36428754 PMC: 9688155. DOI: 10.3390/cancers14225662.

References
1.
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F . Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. Cancer Res. 2018; 78(12):3220-3232. DOI: 10.1158/0008-5472.CAN-17-3415. View

2.
Yang L, Wang B, Qin J, Zhou H, Majumdar A, Peng F . Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Immunopharmacol Immunotoxicol. 2018; 40(1):91-97. DOI: 10.1080/08923973.2017.1417997. View

3.
Yang X, Chen D, Long H, Zhu B . The mechanisms of pathological extramedullary hematopoiesis in diseases. Cell Mol Life Sci. 2020; 77(14):2723-2738. PMC: 11104806. DOI: 10.1007/s00018-020-03450-w. View

4.
Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X . Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9. Adv Sci (Weinh). 2019; 6(18):1901278. PMC: 6755519. DOI: 10.1002/advs.201901278. View

5.
Ma C, Kapanadze T, Gamrekelashvili J, Manns M, Korangy F, Greten T . Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012; 92(6):1199-206. PMC: 3501895. DOI: 10.1189/jlb.0212059. View